Espinoza Octavio's Form 4 filing
Ligand Pharmaceuticals Inc (LGND) · filed Feb 29, 2024
- Accession no.
- 0002001011-24-000028
- Filed
- Feb 29, 2024
- Trade date
- Feb 27-28, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $12.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Espinoza OctavioCIK 0001905248 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2024 | Common Stock | AGrant or awardAcquired | +7,208 | $0.00 | $0 | 28,631 | Direct | |
| Feb 28, 2024 | Common Stock | MOption exerciseAcquired | +799 | $55.75 | +$44,544.25 | 29,430 | Direct | |
| Feb 28, 2024 | Common Stock | MOption exerciseAcquired | +140 | $57.22 | +$8,010.8 | 29,570 | Direct | |
| Feb 28, 2024 | Common Stock | MOption exerciseAcquired | +325 | $58.49 | +$19,009.25 | 29,895 | Direct | |
| Feb 28, 2024 | Common Stock | SSaleDisposed | −140 | $88.46 | −$12,384.4 | 29,755 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2024 | Common Stock | MOption exerciseDisposed | −799 | $0.00 | $0 | 2,869 | Direct | |
| Feb 28, 2024 | Common Stock | MOption exerciseDisposed | −140 | $0.00 | $0 | 7,722 | Direct | |
| Feb 28, 2024 | Common Stock | MOption exerciseDisposed | −325 | $0.00 | $0 | 1,607 | Direct | |
| Feb 27, 2024 | Common Stock | AGrant or awardAcquired | +29,272 | $0.00 | $0 | 29,272 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.